Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 6 | 2023 | 279 | 0.950 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2021 | 5 | 0.760 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2013 | 347 | 0.720 |
Why?
|
| Hypoxia | 3 | 2024 | 107 | 0.570 |
Why?
|
| Respiratory Insufficiency | 4 | 2024 | 148 | 0.530 |
Why?
|
| Sugar Phosphates | 2 | 2013 | 3 | 0.490 |
Why?
|
| Disaccharides | 2 | 2013 | 10 | 0.490 |
Why?
|
| Intensive Care Units | 6 | 2021 | 446 | 0.460 |
Why?
|
| Hospital Mortality | 4 | 2021 | 841 | 0.420 |
Why?
|
| Cannula | 2 | 2024 | 24 | 0.410 |
Why?
|
| Respiration, Artificial | 6 | 2021 | 285 | 0.390 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 69 | 0.380 |
Why?
|
| Lipid A | 1 | 2010 | 70 | 0.330 |
Why?
|
| Shock, Septic | 2 | 2023 | 90 | 0.320 |
Why?
|
| Integrins | 4 | 1997 | 108 | 0.310 |
Why?
|
| Double-Blind Method | 8 | 2024 | 684 | 0.310 |
Why?
|
| Bacterial Infections | 1 | 2010 | 139 | 0.310 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 644 | 0.300 |
Why?
|
| Mucoproteins | 2 | 1997 | 3 | 0.270 |
Why?
|
| Receptors, Lymphocyte Homing | 2 | 1997 | 15 | 0.270 |
Why?
|
| Immunoglobulins | 2 | 1997 | 76 | 0.260 |
Why?
|
| Critical Care | 4 | 2017 | 406 | 0.240 |
Why?
|
| Oxazines | 1 | 2024 | 13 | 0.240 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2004 | 33 | 0.230 |
Why?
|
| Morpholines | 1 | 2024 | 86 | 0.230 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 34 | 0.230 |
Why?
|
| Pyridines | 1 | 2024 | 97 | 0.230 |
Why?
|
| Guideline Adherence | 2 | 2021 | 295 | 0.220 |
Why?
|
| Propensity Score | 1 | 2024 | 132 | 0.220 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 436 | 0.220 |
Why?
|
| Adult | 17 | 2024 | 15709 | 0.210 |
Why?
|
| Humans | 29 | 2024 | 59188 | 0.200 |
Why?
|
| Aged | 14 | 2024 | 13272 | 0.190 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2021 | 11 | 0.190 |
Why?
|
| Male | 18 | 2024 | 27447 | 0.180 |
Why?
|
| Middle Aged | 15 | 2024 | 16209 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 18 | 0.180 |
Why?
|
| Female | 19 | 2024 | 30768 | 0.180 |
Why?
|
| Blood Gas Analysis | 2 | 2017 | 34 | 0.180 |
Why?
|
| Tidal Volume | 2 | 2019 | 34 | 0.180 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5134 | 0.150 |
Why?
|
| Acute Chest Syndrome | 1 | 2017 | 4 | 0.150 |
Why?
|
| Blood Substitutes | 1 | 2017 | 5 | 0.150 |
Why?
|
| Patient Safety | 1 | 2020 | 243 | 0.150 |
Why?
|
| Integrin beta Chains | 1 | 1997 | 2 | 0.150 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 43 | 0.140 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2017 | 40 | 0.140 |
Why?
|
| Protein C | 2 | 2008 | 30 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2017 | 139 | 0.140 |
Why?
|
| Thiamine Deficiency | 1 | 2016 | 6 | 0.130 |
Why?
|
| Thiamine | 1 | 2016 | 19 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 1 | 1997 | 662 | 0.130 |
Why?
|
| Lactic Acid | 1 | 2016 | 70 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 711 | 0.130 |
Why?
|
| APACHE | 3 | 2010 | 51 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2024 | 2434 | 0.120 |
Why?
|
| Shock | 1 | 2015 | 31 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2015 | 53 | 0.120 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1019 | 0.110 |
Why?
|
| Lymphocytes | 1 | 1994 | 193 | 0.110 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 170 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 1446 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2019 | 3093 | 0.100 |
Why?
|
| Gram-Positive Bacteria | 1 | 2011 | 36 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2011 | 54 | 0.090 |
Why?
|
| United States | 5 | 2021 | 7481 | 0.090 |
Why?
|
| Phospholipids | 1 | 2011 | 79 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 42 | 0.090 |
Why?
|
| Acute Disease | 2 | 2024 | 657 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2323 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2011 | 184 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 192 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 281 | 0.080 |
Why?
|
| Choriocarcinoma | 1 | 2008 | 5 | 0.080 |
Why?
|
| Incidence | 2 | 2019 | 1232 | 0.080 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2008 | 10 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2010 | 553 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 30 | 0.080 |
Why?
|
| Critical Illness | 2 | 2010 | 332 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 67 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 807 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 3 | 1997 | 90 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2008 | 469 | 0.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 42 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2020 | 187 | 0.060 |
Why?
|
| Pyridazines | 1 | 2024 | 6 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2024 | 5960 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2024 | 123 | 0.060 |
Why?
|
| Insulin | 1 | 2008 | 686 | 0.060 |
Why?
|
| Polymyxin B | 1 | 2023 | 8 | 0.060 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2023 | 4 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2008 | 485 | 0.060 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 48 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 202 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 169 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 108 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2017 | 917 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2003 | 23 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 1906 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 72 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 292 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 1997 | 453 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2003 | 233 | 0.050 |
Why?
|
| Neuromuscular Blockade | 1 | 2021 | 9 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 17 | 0.050 |
Why?
|
| Prone Position | 1 | 2021 | 27 | 0.050 |
Why?
|
| HIV Infections | 1 | 2008 | 915 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2021 | 45 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2021 | 61 | 0.050 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 1997 | 6 | 0.050 |
Why?
|
| Patient Positioning | 1 | 2021 | 41 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2011 | 2886 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 219 | 0.050 |
Why?
|
| Heart | 1 | 2003 | 274 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 49 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 565 | 0.040 |
Why?
|
| Cell Adhesion | 3 | 1997 | 211 | 0.040 |
Why?
|
| Prognosis | 1 | 2004 | 1564 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2019 | 27 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 170 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 56 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1997 | 500 | 0.040 |
Why?
|
| Transfection | 2 | 1997 | 671 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 5060 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 187 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2019 | 99 | 0.040 |
Why?
|
| Lung | 1 | 2003 | 822 | 0.040 |
Why?
|
| Microvilli | 1 | 1997 | 4 | 0.040 |
Why?
|
| Methemoglobinemia | 1 | 2017 | 5 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 2017 | 20 | 0.040 |
Why?
|
| Jehovah's Witnesses | 1 | 2017 | 17 | 0.040 |
Why?
|
| Placebos | 1 | 2017 | 72 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2017 | 60 | 0.040 |
Why?
|
| Epitope Mapping | 1 | 1997 | 46 | 0.040 |
Why?
|
| North America | 1 | 2017 | 114 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 1277 | 0.040 |
Why?
|
| Cations | 1 | 1997 | 63 | 0.040 |
Why?
|
| Oximetry | 1 | 2017 | 48 | 0.040 |
Why?
|
| Serine | 1 | 1997 | 83 | 0.040 |
Why?
|
| Leukocytes | 1 | 1997 | 107 | 0.040 |
Why?
|
| Pregnancy | 1 | 2004 | 2352 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 75 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 306 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 520 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 704 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2021 | 519 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 787 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 196 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 373 | 0.030 |
Why?
|
| Cross Infection | 1 | 2017 | 150 | 0.030 |
Why?
|
| Ligands | 1 | 1997 | 421 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 4314 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 1997 | 867 | 0.030 |
Why?
|
| Central Venous Pressure | 1 | 2015 | 13 | 0.030 |
Why?
|
| Furosemide | 1 | 2015 | 17 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2015 | 19 | 0.030 |
Why?
|
| Animals | 4 | 2017 | 19559 | 0.030 |
Why?
|
| Diuretics | 1 | 2015 | 58 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 263 | 0.030 |
Why?
|
| Risk Factors | 1 | 2004 | 4995 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 1994 | 54 | 0.030 |
Why?
|
| Manganese | 1 | 1994 | 24 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 198 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 1994 | 28 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1203 | 0.030 |
Why?
|
| Polymers | 1 | 2017 | 315 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 134 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 1971 | 0.030 |
Why?
|
| Cell Line | 2 | 1997 | 2011 | 0.030 |
Why?
|
| Rats | 1 | 1997 | 1904 | 0.030 |
Why?
|
| Organ Dysfunction Scores | 1 | 2013 | 17 | 0.030 |
Why?
|
| Protein Binding | 1 | 1997 | 1542 | 0.030 |
Why?
|
| Mice | 2 | 1997 | 10237 | 0.030 |
Why?
|
| Intestines | 1 | 1993 | 156 | 0.030 |
Why?
|
| Hypertension | 1 | 2017 | 598 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 387 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 236 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 1993 | 276 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 609 | 0.020 |
Why?
|
| Respiratory Dead Space | 1 | 2008 | 2 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 4 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 14 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 66 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 228 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 309 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 117 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 576 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 174 | 0.020 |
Why?
|
| Drug Costs | 1 | 2005 | 59 | 0.020 |
Why?
|
| Software | 1 | 2008 | 365 | 0.020 |
Why?
|
| Muscles | 1 | 1984 | 171 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 1544 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 691 | 0.010 |
Why?
|
| Vascular Capacitance | 1 | 2003 | 2 | 0.010 |
Why?
|
| Cardiac Volume | 1 | 2003 | 7 | 0.010 |
Why?
|
| Ventricular Function | 1 | 2003 | 21 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 445 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2003 | 30 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2003 | 44 | 0.010 |
Why?
|
| Diastole | 1 | 2003 | 89 | 0.010 |
Why?
|
| HIV-1 | 1 | 2008 | 706 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 5912 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1997 | 31 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 14 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1997 | 31 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1997 | 59 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1997 | 253 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1993 | 15 | 0.010 |
Why?
|
| Fibronectins | 1 | 1993 | 43 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1993 | 2097 | 0.000 |
Why?
|
| Rhodamines | 1 | 1984 | 20 | 0.000 |
Why?
|
| Glycerol | 1 | 1984 | 30 | 0.000 |
Why?
|
| Muscle Relaxation | 1 | 1984 | 25 | 0.000 |
Why?
|
| Rabbits | 1 | 1984 | 330 | 0.000 |
Why?
|
| Models, Biological | 1 | 1984 | 1137 | 0.000 |
Why?
|